Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

Tim - haaving just read your previous post, you need to study OXB properly sir. You are way out of understanding on it.
secondly
Knackers good morning, excellent clear and well thought out post above. I happen to go along with your reasoning rather closely, eg end of ist Q 06 for a Trovax outlicence, (and Tuco's 50p party which would follow).
They do want it out of the way, to concentrate on Neuro and Parkinsons.
Lets NOT forget Metxia, which is just 9 months behind. It may suprise us in 2006, and of coure, TriVax for Renal cancer may well be fast-tracked. Now that would be a very lucrative RNS as it has so many implications for partnering and funding.

Cheers
H.